Current Edition

Current Features

Advertisement

Current Edition

Current features

FDA Focus on the Safety of Gene Therapy Products

Within the past 6 years, the US Food and Drug Administration (FDA) has approved a growing number of cellular and gene therapy products to treat a variety of conditio...
Continue Reading →
Current features

Transparent, Pret-a-porter Operations Quality Measurement & Other 2024 Priorities for Drug Manufacturers & the Supply Chain

In Life Sciences manufacturing quality and compliance, the global digitalisation drive continues a-pace as the pressure builds to innovate, collaborate and contain c...
Continue Reading →
Current features

Achieving GCP Compliance in Oncology Trials: The Balance between Obligation, Idealism and Realism

Compliance with GCP provides assurance that the data and reported results of clinical investigations are credible and accurate and that the rights, safety, and confi...
Continue Reading →
Current features

Enhancing the Data Journey in Oncology Clinical Trials

Clinical trials are the springboard for progress in modern healthcare, guiding the development and evaluation of new treatments and next-generation therapies for pat...
Continue Reading →
Current features

Regenerative Medicine: Hype and Hope or Safety and Efficacy?

Regenerative medicine, and the underlying stem cell technology on which it is based, offer considerable hope to patients suffering from trauma and acute or chronic d...
Continue Reading →
Current features

Revolutionising Hypertension Management Through Personalised, Data-driven Dose Optimisation

In the late 1990s, Pfizer’s revenue stream was predominantly fuelled from the sales of antihypertensive drugs. The climax, so to speak, of its rigorous anti-hyperten...
Continue Reading →

Company Profiles